Early amyloid accumulation and APOE‐ε4 are associated with reduced non‐rapid eye movement slow‐wave activity in cognitively unimpaired adults

Abstract Background Poor sleep is associated with cognitive decline, and ∼45% of Alzheimer’s disease (AD) patients experience sleep disturbances. Emerging evidence suggests that reduced non‐rapid eye movement (NREM) slow wave sleep (SWS) is linked to amyloid accumulation and APOE ε4‐related genetic vulnerability to AD. Here, we investigate the effects of amyloid and APOE status on SWS, and their interaction, in a cohort of cognitively unimpaired (CU) individuals at higher risk of AD. Method We analyzed data from 80 sleep medication free participants (65.26 years old on average, 55% females, Table 1) from the AlfaSleep project, which involves characterization with polysomnography, APOE genotyping, CSF amyloid‐β (Aβ) 40 and Aβ42 (Roche NeuroToolKit), and [ 18 F]flutemetamol‐PET, among other measures. Participants were classified as amyloid positive (A+) using either CSF Aβ 42/40 ratio (<0.071, N = 75), or amyloid PET (>12 Centiloids, N = 5) thresholds for early amyloid deposition. We computed average power spectral densities (PSD) from NREM sleep 30‐s epochs in frontal electroencephalogram channels, and power of slow oscillations (SO), delta and slow wave activity (SWA) as the area under the PSD curve between 0.5‐1Hz, 1‐4Hz and 0.5‐4Hz, respectively. We log‐transformed SWS metrics due to non‐normal distribution. We used linear regression models to test the main effect of amyloid or APOE status on SWS metrics in separated models, and next we entered both in the same model. Finally, we the tested interaction between APOE and amyloid status on SWS metrics. Models were adjusted by age, sex, and apnea‐hypopnea index (AHI). Result Both A+ status and APOE ‐ε4 carriership were associated with significantly lower power in SO and SWA in separated models (Figure 1A). When combining both in the same model, only the effect of APOE on SO power remained significant, as well as a trend for lower SWA (Figure 1B). Interaction analyses yielded no significance. Conclusion Early amyloid accumulation and APOE ‐ε4 carriership are associated with SWS disruption in CU adults, with APOE ‐ε4 carriers probably being particularly vulnerable to SWS disruption. Longitudinal studies spanning younger age individuals are needed to characterize the contribution of APOE ‐ε4 to SWS disruption and to test whether preventive interventions targeting SWS could help to reduce AD dementia risk.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-12-01
DOI
https://doi.org/10.1002/alz.086410
Primary Topic
Circadian rhythm and melatonin
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early amyloid accumulation and APOE‐ε4 are associated with reduced non‐rapid eye movement slow‐wave activity in cognitively unimpaired adults

Núria Tort‐Colet, Amaia Muñoz‐Lopetegi, Thomas Mueggler, Aurora Arqueros et al.
Alzheimer s & Dementia
Circadian rhythm and melatonin
article

Early amyloid accumulation and APOE‐ε4 are associated with reduced non‐rapid eye movement slow‐wave activity in cognitively unimpaired adults

Núria Tort‐Colet, Amaia Muñoz‐Lopetegi, Thomas Mueggler, Aurora Arqueros, Gonzalo Sánchez‐Benavides, José Luís Molinuevo, Sebastian C. Holst, Iva Knezevic, Pilar Garcés, Juan Domingo Gispert, Laura Hernandez Perez, Ana Fernández‐Arcos, Oriol Grau‐Rivera, Henrik Zetterberg, Laura S Stankeviciute, Marc Suárez‐Calvet, Carolina Minguillón, Kaj Blennow, Álex Iranzo
article en

Abstract

Abstract Background Poor sleep is associated with cognitive decline, and ∼45% of Alzheimer’s disease (AD) patients experience sleep disturbances. Emerging evidence suggests that reduced non‐rapid eye movement (NREM) slow wave sleep (SWS) is linked to amyloid accumulation and APOE ε4‐related genetic vulnerability to AD. Here, we investigate the effects of amyloid and APOE status on SWS, and their interaction, in a cohort of cognitively unimpaired (CU) individuals at higher risk of AD. Method We analyzed data from 80 sleep medication free participants (65.26 years old on average, 55% females, Table 1) from the AlfaSleep project, which involves characterization with polysomnography, APOE genotyping, CSF amyloid‐β (Aβ) 40 and Aβ42 (Roche NeuroToolKit), and [ 18 F]flutemetamol‐PET, among other measures. Participants were classified as amyloid positive (A+) using either CSF Aβ 42/40 ratio (<0.071, N = 75), or amyloid PET (>12 Centiloids, N = 5) thresholds for early amyloid deposition. We computed average power spectral densities (PSD) from NREM sleep 30‐s epochs in frontal electroencephalogram channels, and power of slow oscillations (SO), delta and slow wave activity (SWA) as the area under the PSD curve between 0.5‐1Hz, 1‐4Hz and 0.5‐4Hz, respectively. We log‐transformed SWS metrics due to non‐normal distribution. We used linear regression models to test the main effect of amyloid or APOE status on SWS metrics in separated models, and next we entered both in the same model. Finally, we the tested interaction between APOE and amyloid status on SWS metrics. Models were adjusted by age, sex, and apnea‐hypopnea index (AHI). Result Both A+ status and APOE ‐ε4 carriership were associated with significantly lower power in SO and SWA in separated models (Figure 1A). When combining both in the same model, only the effect of APOE on SO power remained significant, as well as a trend for lower SWA (Figure 1B). Interaction analyses yielded no significance. Conclusion Early amyloid accumulation and APOE ‐ε4 carriership are associated with SWS disruption in CU adults, with APOE ‐ε4 carriers probably being particularly vulnerable to SWS disruption. Longitudinal studies spanning younger age individuals are needed to characterize the contribution of APOE ‐ε4 to SWS disruption and to test whether preventive interventions targeting SWS could help to reduce AD dementia risk.

Alzheimer s & DementiaVol. 20(S7)
Roche (Switzerland) (CH), Lundbeck (Denmark) (DK), Sahlgrenska University Hospital (SE), Instituto de Salud Carlos III (ES), Biomedical Research Networking Center on Neurodegenerative Diseases (ES), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES), Pasqual Maragall Foundation (ES), Hospital Clínic de Barcelona (ES), UK Dementia Research Institute (GB), Barcelonaβeta Brain Research Center (ES), Hospital Del Mar (ES), Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (ES), National Hospital for Neurology and Neurosurgery (GB), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), University College London (GB), University of Gothenburg (SE)
Openalex Percentile: Top 75%
Circadian rhythm and melatonin
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.